Agrigenomics Yields a Next-Gen Cornucopia

Gene editing technology takes agricultural biotechnology beyond transgenic technology, which transfers “as is” genes from one species to another. Essentially, gene editing is more refined than transgenesis. This difference may justify the view that gene edited plants are not, like transgenic plants, genetically modified organisms (GMOs). Regulatory requirements and consumer attitudes may hang in the balance.

Spotlight

Scientific Bioprocessing

We develop leading-edge instruments that make the work of cell scientists, like yourself, easier and more reproducible as you seek to de-risk new cell-based therapeutic agents, grow artificial tissue faster and discover new drugs. We manufacture and distribute a range of cutting-edge optical sensor and desktop production systems for cell scientists.

OTHER ARTICLES
MedTech

Laboratory Information Management System for Biotech Labs: Significance & Benefits

Article | July 13, 2022

If you have ever visited the testing laboratory of a large biotechnology company, you will be aware that managing the laboratory's operations single-handedly is no easy task. The greater the size of a lab, the more research and testing activities it must accommodate. A variety of diagnostic tests are prescribed for patients in order to detect various diseases. For example, it may include blood glucose testing for diabetics, lipid panel, or liver panel tests for evaluating cardiac risk and liver function, cultures for diagnosing infections, thyroid function tests, and others. Laboratory management solutions such as laboratory information management systems (LIMS) and other software play a significant role in managing various operational data at biotech laboratories. It is one of the important types of software developed to address thedata management and regulatory challenges of laboratories. The software enhances the operational efficiency of biotech labs by streamlining workflows, proper record-keeping, and eradicating the need for manually maintaining data. What Are the Benefits of Laboratory Information Management Software in Biotechnology? As the trends of digitization and technology continue to create deeper inroads into the biotechnology sector, a significant rise in the adoption of innovative medical software solutions, such as LIMS, is being witnessed for managing research data, testing reports, and post-research results globally. Here are a few reasons that are encouraging biotech facilities to adopt LIMS solutions Real-Time Data Collection and Tracking Previously, collecting and transporting samples was a tedious and time-consuming task. However, the adoption of LIMS with innovative tracking modules has made the job easier. The real-time sample tracking feature of LIMS has made it possible for personnel to collect the research data in real-time and manage and control the workflow with a few mouse clicks on the screen. Increase Revenue LIMS makes it possible to test workflows while giving users complete control over the testing process. A laboratory is able to collect data, schedule equipment maintenance or upgrades, enhance operational efficiency, and maintain a lower overhead with the help of the LIMS, thereby increasing revenue. Streamlined Workflow With its completion monitoring, LIMS speeds up laboratory workflows and keeps track of information. It assigns tasks to the specialist along with keeping a real-time track of the status and completion of each task. LIMS is integrated into the laboratory using lab information, which ultimately speeds up internal processes and streamlines the workflow. Automatic Data Exchange LIMS solutions store data in a centralized database. Automated transfer of data between departments and organizations is one of the major features of LIMS. Through its automated information exchange feature, LIMS improves internal operations, decreases the reporting time for data sharing, and assists in faster decision-making. Final Thoughts As the healthcare sector continues to ride the wave of digital transformation, biotech laboratories are emphasizing adopting newer technologies to keep up with the changes. Citing this trend, laboratory information management systems are becoming crucial for biotech and medical organizations for maintaining research data, instant reporting, and managing confidential, inventory, and financial data with centralized data storage.

Read More
Medical

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | July 14, 2022

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More
MedTech

Biotech in 2022

Article | July 20, 2022

The robust global channel of more than, 800 gene and cell curatives presently in trials will produce clinical readouts in 2022, revealing what lies ahead for advanced curatives. The impact will be felt in 2022, no matter how you slice it. Eventually, how well industry and non-supervisory bodies unite to produce new frameworks for advanced therapies will shape the year 2022 and further. Pacific Northwest talent will continue to contribute to the advancement of gene and cell curatives in both the short and long term, thanks to its deep pool of ground-breaking scientific developers, entrepreneurial directorial leadership, largely skilled translational scientists, and endured bio manufacturing technicians. We may see continued on-life science fund withdrawal from biotech in 2021, but this can be anticipated as a strong comeback in 2022 by biotech industry, backed by deep-pocketed life science investors who are committed to this sector. A similar investment, combined with pharma's cash-heavy coffers, can result in increased junction and acquisition activity, which will be a challenge for some but an occasion for others. Over the last five years, investment interest in Seattle and the Pacific Northwest has grown exponentially, from Vancouver, British Columbia, to Oregon. The region's explosive portfolio of new biotech companies, innovated out of academic centres, demonstrates the region's growing recognition of scientific invention. This created a belief that continued, especially because Seattle's start-ups and biotech enterprises are delivering on their pledge of clinical and patient impact. Talent and staffing will continue to be difficult to find. It's a CEO's market, but many of these funds' return, and are not rising in proportion to the exorbitant prices they're paying to enter deals. This schism has become particularly pronounced in 2021. Hence, everyone in biotech is concerned about reclamation and retention.

Read More
Research

2022 U.S. Market Research Report with COVID-19 Forecasts2

Article | July 11, 2022

The global biotechnology market is expected to grow at a compound annual growth rate (CAGR) of 13.9 percent from 2022 to 2030, with a value estimated at USD 1,023.92 billion in 2021. The market is being propelled by strong government support in the form of initiatives aimed at modernizing the regulatory framework, improving approval processes and reimbursement policies, and standardizing clinical studies. The growing presence of personalized medicine and an increasing number of orphan drug formulations are opening up new avenues for biotechnology applications and driving the influx of emerging and innovative biotechnology companies, which is driving market revenue even further. The 2022 Biotech Research and Development Market Research Report is one of the most comprehensive and in-depth assessments of the industry in the United States, containing over 100 data sets spanning the years 2013 to 2026. This Kentley Insights report contains historical and forecasted market size, product lines, profitability, financial ratios, BCG matrix, state statistics, operating expense details, organizational breakdown, consolidation analysis, employee productivity, price inflation, pay bands for the top 20 industry jobs, trend analysis and forecasts on companies, locations, employees, payroll, and much more. Companies in the Biotech Research and Development industry are primarily engaged in biotechnology research and experimental development. Biotechnology research and development entails the investigation of the use of microorganisms and cellular and bimolecular processes to create or modify living or non-living materials. This biotechnology research and development may result in the development of new biotechnology processes or prototypes of new or genetically altered products that can be replicated, used, or implemented by various industries. This report was created using the findings of extensive business surveys and econometrics. The professionals follow reports with accurate and apt information on market sizing, benchmarking, strategic planning, due diligence, cost-cutting, planning, understanding industry dynamics, forecasting, streamlining, gap analysis, and other ana

Read More

Spotlight

Scientific Bioprocessing

We develop leading-edge instruments that make the work of cell scientists, like yourself, easier and more reproducible as you seek to de-risk new cell-based therapeutic agents, grow artificial tissue faster and discover new drugs. We manufacture and distribute a range of cutting-edge optical sensor and desktop production systems for cell scientists.

Related News

MedTech

GP-write Partners with DNA Script to Accelerate DNA-Writing Technology and Accessibility

Genome Project-write | October 18, 2021

GP-write’s CAD is a one-stop shop for microbe, plant and animal genome writing and redesign. Its automated workflow allows users to rapidly upload a genome, redesign it and synthesize the new sequence. The tool enables researchers to directly order synthetic DNA or related products and services from GP-write’s affiliated members. DNA Script’s SYNTAX System, a benchtop DNA printer powered by their groundbreaking enzymatic DNA synthesis (EDS) technology, enables users to print sequences designed on GP-write’s CAD tool right in their lab. The first-of-its-kind DNA printer expedites workflows, making DNA writing as simple and efficient as next-generation sequencing. DNA Script will host a roundtable at the GP-write 5.0 conference on October 22 at 12:30 p.m. ET to engage attendees in a discussion centered on biosecurity as it relates to emerging technologies, including GP-write’s new CAD tool and DNA Script’s SYNTAX System. “We’re pleased to join GP-write and their industrial partners to drive innovation on the forefront of DNA printing technologies. Just as NGS, or DNA 'read,' and CRISPR, or DNA 'edit,' have brought significant advances to research and clinical care, we believe the broad accessibility of synthetic DNA printing, or DNA 'write,' offered by our SYNTAX System will be equally transformative and power the next bio-revolution.” Thomas Ybert, co-founder and CEO of DNA Script GP-write President and General Counsel, Amy Cayne Schwartz, notes that the organizations are partnering to work toward realizing “a shared vision of a future where writing genomes is facile, democratized and safely accessible.” Schwartz explains that “this will open up new frontiers for development of novel therapeutics and solutions for environmental health.” About Genome Project-write GP-write, conceived as a sequel to the Human Genome Project, applies lessons learned from HGP to pursue scientific exploration fully integrated with the development of genome engineering technologies. The primary goal of the project is to drive dramatic cost reductions and expedite whole-genome writing and redesign over the next decade, empowering researchers to uncover complex biological behavior and reprogram organisms to address defining global challenges in medicine, biotechnology and environmental health. About DNA Script Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, allowing this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy.

Read More

New Device Permits a Closer Look at Previously Inaccessible Areas of the Genome

Technology Networks | November 25, 2019

Expansions of DNA repeats are very hard to analyze. A method developed by researchers at the Max Planck Institute for Molecular Genetics in Berlin allows for a detailed look at these previously inaccessible regions of the genome. It combines nanopore sequencing, stem cell, and CRISPR-Cas technologies. The method could improve the diagnosis of various congenital diseases and cancers in the future. Large parts of the genome consist of monotonous regions where short sections of the genome repeat hundreds or thousands of times. But expansions of these "DNA repeats" in the wrong places can have dramatic consequences, like in patients with Fragile X syndrome, one of the most commonly identifiable hereditary causes of cognitive disability in humans. However, these repetitive regions are still regarded as an unknown territory that cannot be examined appropriately, even with modern methods. A research team led by Franz-Josef Müller at the Max Planck Institute for Molecular Genetics in Berlin and the University Hospital of Schleswig-Holstein in Kiel recently shed light on this inaccessible region of the genome. Müller's team was the first to successfully determine the length of genomic tandem repeats in patient-derived stem cell cultures. The researchers additionally obtained data on the epigenetic state of the repeats by scanning individual DNA molecules. The method, which is based on nanopore sequencing and CRISPR-Cas technologies, opens the door for research into repetitive genomic regions, and the rapid and accurate diagnosis of a range of diseases.

Read More

Synthego Launches Genome Engineering for iPS Cells

GEN | October 23, 2019

Synthego’s newest offering applies genome engineering in order to address a longtime challenge in research and drug development—the dearth of high-quality, physiologically relevant biological models needed for translational medicine. The provider of genome engineering products and services this week launched a genome engineering service for induced pluripotent stem (iPS) cells—an expansion of automated cell editing capabilities that according to Synthego is designed to achieve extremely high editing efficiency of iPS cells at an industrial scale. Synthego reasons that iPS cells can provide one of the most reliable and accurate models for disease because they allow researchers to create patient-specific variations. Yet iPS cells created through the reprogramming of human adult cells have traditionally been difficult to handle and modify genetically. Synthego’s new offering of iPS cells includes modification by removal of gene function (knockout), single nucleotide variation, protein tagging and other knock-ins, all with the goal of enabling scientists to generate edits at a massive scale to accelerate research and disease modeling.

Read More

MedTech

GP-write Partners with DNA Script to Accelerate DNA-Writing Technology and Accessibility

Genome Project-write | October 18, 2021

GP-write’s CAD is a one-stop shop for microbe, plant and animal genome writing and redesign. Its automated workflow allows users to rapidly upload a genome, redesign it and synthesize the new sequence. The tool enables researchers to directly order synthetic DNA or related products and services from GP-write’s affiliated members. DNA Script’s SYNTAX System, a benchtop DNA printer powered by their groundbreaking enzymatic DNA synthesis (EDS) technology, enables users to print sequences designed on GP-write’s CAD tool right in their lab. The first-of-its-kind DNA printer expedites workflows, making DNA writing as simple and efficient as next-generation sequencing. DNA Script will host a roundtable at the GP-write 5.0 conference on October 22 at 12:30 p.m. ET to engage attendees in a discussion centered on biosecurity as it relates to emerging technologies, including GP-write’s new CAD tool and DNA Script’s SYNTAX System. “We’re pleased to join GP-write and their industrial partners to drive innovation on the forefront of DNA printing technologies. Just as NGS, or DNA 'read,' and CRISPR, or DNA 'edit,' have brought significant advances to research and clinical care, we believe the broad accessibility of synthetic DNA printing, or DNA 'write,' offered by our SYNTAX System will be equally transformative and power the next bio-revolution.” Thomas Ybert, co-founder and CEO of DNA Script GP-write President and General Counsel, Amy Cayne Schwartz, notes that the organizations are partnering to work toward realizing “a shared vision of a future where writing genomes is facile, democratized and safely accessible.” Schwartz explains that “this will open up new frontiers for development of novel therapeutics and solutions for environmental health.” About Genome Project-write GP-write, conceived as a sequel to the Human Genome Project, applies lessons learned from HGP to pursue scientific exploration fully integrated with the development of genome engineering technologies. The primary goal of the project is to drive dramatic cost reductions and expedite whole-genome writing and redesign over the next decade, empowering researchers to uncover complex biological behavior and reprogram organisms to address defining global challenges in medicine, biotechnology and environmental health. About DNA Script Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, allowing this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy.

Read More

New Device Permits a Closer Look at Previously Inaccessible Areas of the Genome

Technology Networks | November 25, 2019

Expansions of DNA repeats are very hard to analyze. A method developed by researchers at the Max Planck Institute for Molecular Genetics in Berlin allows for a detailed look at these previously inaccessible regions of the genome. It combines nanopore sequencing, stem cell, and CRISPR-Cas technologies. The method could improve the diagnosis of various congenital diseases and cancers in the future. Large parts of the genome consist of monotonous regions where short sections of the genome repeat hundreds or thousands of times. But expansions of these "DNA repeats" in the wrong places can have dramatic consequences, like in patients with Fragile X syndrome, one of the most commonly identifiable hereditary causes of cognitive disability in humans. However, these repetitive regions are still regarded as an unknown territory that cannot be examined appropriately, even with modern methods. A research team led by Franz-Josef Müller at the Max Planck Institute for Molecular Genetics in Berlin and the University Hospital of Schleswig-Holstein in Kiel recently shed light on this inaccessible region of the genome. Müller's team was the first to successfully determine the length of genomic tandem repeats in patient-derived stem cell cultures. The researchers additionally obtained data on the epigenetic state of the repeats by scanning individual DNA molecules. The method, which is based on nanopore sequencing and CRISPR-Cas technologies, opens the door for research into repetitive genomic regions, and the rapid and accurate diagnosis of a range of diseases.

Read More

Synthego Launches Genome Engineering for iPS Cells

GEN | October 23, 2019

Synthego’s newest offering applies genome engineering in order to address a longtime challenge in research and drug development—the dearth of high-quality, physiologically relevant biological models needed for translational medicine. The provider of genome engineering products and services this week launched a genome engineering service for induced pluripotent stem (iPS) cells—an expansion of automated cell editing capabilities that according to Synthego is designed to achieve extremely high editing efficiency of iPS cells at an industrial scale. Synthego reasons that iPS cells can provide one of the most reliable and accurate models for disease because they allow researchers to create patient-specific variations. Yet iPS cells created through the reprogramming of human adult cells have traditionally been difficult to handle and modify genetically. Synthego’s new offering of iPS cells includes modification by removal of gene function (knockout), single nucleotide variation, protein tagging and other knock-ins, all with the goal of enabling scientists to generate edits at a massive scale to accelerate research and disease modeling.

Read More

Events